Tivanisiran (SYL1001) is a siRNA used for the study of dry eye disease. Tivanisiran was designed to silence transient receptor potential vanilloid 1 (TRPV1)[1].
In vitro transfection of tivanisiran was shown to produce a 50-60% decrease in TRPV1 mRNA levels[1][2].
[1]. Anne-Marie Bleau, et al. Development of tivanisiran, a topical siRNA designed to
[2]. Javier Moreno-MontaÑÉs, et al. Tivanisiran, a novel siRNA for the treatment of dry eye disease. Expert Opin Investig Drugs. 2018 Apr;27(4):421-426.